Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.

Abstract	The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.
Authors	M Kelli Jordan, Aaron H Burstein, Diane Rock-Kress, Raul M Alfaro, Alice K Pau, Joseph A Kovacs, Stephen C Piscitelli
Journal	Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 48 Issue 2 Pg. 635-7 (Feb 2004) ISSN: 0066-4804 [Print] United States
PMID	14742225 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Anti-Infective Agents Sulfadiazine
Topics	Anti-Infective Agents (administration & dosage, blood, pharmacokinetics) Area Under Curve Cross-Over Studies HIV Infections (complications, metabolism) Half-Life Humans Models, Biological Sulfadiazine (administration & dosage, blood, pharmacokinetics) Toxoplasmosis (drug therapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!